Uses and limitations of randomization-based efficacy estimators

DOI10.1191/0962280205sm406oazbMath1122.62376WikidataQ81247869 ScholiaQ81247869MaRDI QIDQ5424959

Ian R. White

Publication date: 7 November 2007

Published in: Statistical Methods in Medical Research (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1191/0962280205sm406oa

Mathematics Subject Classification ID

62P10: Applications of statistics to biology and medical sciences; meta analysis

62N02: Estimation in survival analysis and censored data

Related Items

Instrumental variable estimation of early treatment effect in randomized screening trials, A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments, A Comparison of Methods for Estimating the Causal Effect of a Treatment in Randomized Clinical Trials Subject to Noncompliance

Uses Software

• Stata
• stcomply

Cites Work

• Correcting for non-compliance in randomized trials using rank preserving structural failure time models
• Bayesian inference for causal effects in randomized experiments with noncompliance
• Semiparametric instrumental variable estimation of treatment response models.
• Principal Stratification in Causal Inference
• A Causal Proportional Hazards Estimator for the Effect of Treatment Actually Received in a Randomized Trial with All-or-Nothing Compliance
• Some Surprising Results about Covariate Adjustment in Logistic Regression Models
• Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes
• A geometric approach to assess bias due to omitted covariates in generalized linear models
• Estimating Outcome Distributions for Compliers in Instrumental Variables Models
• Assessing the effect of an influenza vaccine in an encouragement design
• Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests
• Correcting for non-compliance in randomized trials using structural nested mean models